R&D expense · 2018–2025

Goodrx Holdings R&D expense

$121M−2.2% · FY2025

Goodrx Holdings (GDRX) reported $121M in R&D expense for fiscal 2025, −2.2% year on year.

$43.9M2018$29.3M2019$61.8M2020$126M2021$143M2022$136M2023$124M2024$121M2025
Goodrx Holdings — R&D expense, 2018–2025
Fiscal yearR&D expenseChangeFiling
FY20252025-12-31$121M−2.2%Open →
FY20242024-12-31$124M−8.9%Open →
FY20232023-12-31$136M−5.1%Open →
FY20222022-12-31$143M+13.7%Open →
FY20212021-12-31$126M+103.6%Open →
FY20202020-12-31$61.8M+111.0%Open →
FY20192019-12-31$29.3M−33.2%Open →
FY20182018-12-31$43.9M—Open →

R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.

Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2018–2025 compound annual growth +15.6%

R&D expense at companies of similar size

Full ranking by R&D expense →

Cite this page

Ready-made references for the figures on this page, as published on September 25, 2026.

Wikipedia

{{cite web |title=Goodrx Holdings R&D expense |url=https://companiesranked.com/en/company/goodrx-holdings/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}

APA 7

CompaniesRanked. (September 25, 2026). Goodrx Holdings R&D expense. CompaniesRanked. https://companiesranked.com/en/company/goodrx-holdings/research-and-development-expense

BibTeX

@misc{companiesranked-en-company-goodrx-holdings-research-and-development-expense-2026,
  author       = {{CompaniesRanked}},
  title        = {{Goodrx Holdings R\&D expense}},
  year         = {2026},
  howpublished = {\url{https://companiesranked.com/en/company/goodrx-holdings/research-and-development-expense}},
  note         = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
  urldate      = {2026-09-25}
}

The filing itself

The numbers above are read from this document: 10-K · 0001809519-26-000031 · February 26, 2026

{{cite web |title=Goodrx Holdings R&D expense — 10-K (0001809519-26-000031) |url=https://www.sec.gov/Archives/edgar/data/1809519/000180951926000031/gdrx-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}

The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.

← Goodrx Holdings overview